Received: 11 May 2022
Accepted: 16 November 2022
First Online: 29 November 2022
: The present study was a single-center, single-arm trial conducted at the Hiroshima University Hospital. This study was carried out in accordance with the Declaration of Helsinki and the.Hiroshima University Hospital Institutional Ethics Committee approved this study (E-2176). The data were analyzed anonymously, and informed consent was obtained in the form of opt-out on the website.
: Not applicable.
: Michio Imamura has received research funding from Bristol-Myers Squibb and AbbVie. Hiroshi Aikata has received honoraria from Eisai and Bayer. Tsutomu Ueda has received research funding from Ono Pharmaceutical. Tatsuo Ichinohe has received honoraria from Bristol-Myers Squibb, Celgene, Janssen Pharma and Kyowa Kirin and research funding from Astellas Pharma, Chugai Pharma, CSL Behring, Eisai, FUJIFILM Wako Chemicals, Kyowa Kirin, Ono Pharma, Pfizer, Nippon Shinyaku, MSD, Otsuka Pharma, Repertoire Genesis Inc., Dainippon Sumitomo Pharma, Taiho Pharma, Takara Bio, Takeda Pharma and Zenyaku Kogyo. Kazuaki Chayama has received honoraria from Bristol-Myers Squibb, MSD K.K., AbbVie, Gilead Science, Dainippon Sumitomo Pharma and Mitsubishi Tanabe Pharma and research funding from Gilead Science, Dainippon Sumitomo Pharma, MSD K.K., AbbVie, Eisai, TORAY, Otsuka Pharma, Chugai Pharma, Takeda Pharma and Roche. Other authors declare no competing interests.